News Amicus set for share of Fabry market after NICE approval England and Wales’ cost effectiveness watchdog NICE has given a final recommendation to a new treatment for the rare Fabry disease.
R&D Going wide on immune system activation, with Jeffrey Meckler Indaptus CEO Jeff Meckler discusses his company's unconventional approach to immunotherapy, based on activating a wide swath of the immune system.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
